Pharmaceutical News and Articles

RotaTeq Approved - Merck & Co., Inc. - Treatment for Prevention of Rotavirus Gastroenteritis

RotaTeq is an oral, three-dose vaccine given to infants between the ages of six to 32 weeks for the prevention of rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children.

Related Articles:

FDA Vaccines Advisory Committee Unanimously Agrees that Clinical Data from 70,000-Infant Phase III Trials Support the Efficacy and Safety of Rotateq, Merck's Investigational Vaccine for Rotavirus Gastroenteritis - December 14, 2005

Merck Announces that FDA Has Accepted For Review Biologics License Applications for Rotateq and Zostavax - June 29, 2005

Merck Submits Biologics License Application to FDA for Rotateq, an Investigational Vaccine for Rotavirus - April 11, 2005

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Aug | Oct | Dec

MedNotes
Advertisement

(web2)